Southern EU states present unified front in drug talks

Folks an article on the intensified pricing collaboration activities among European countries. This has been a long debate for years but it seems more concrete steps are undertaken. Its a pity that countries still don't realize that engaging with the industry on different and novel payment models is more promising than the ever increasing eagerness on pure cost mindset "collaboration". Affordability is an important criterium and can be adressed differently, all these joint purchasing efforts however will only create more inefficiencies and bureaucracy and most likely increase time to access for patients, especially those with rare diseases. It ignores the fundamental economic principle of price differntiation in accordance withbthe exonomic situation and circumstances in every country. Lets hope they can prove me wrong on this one.